2024
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.Peer-Reviewed Original ResearchConceptsRandomized phase II trialCD4/CD8 T cellsT cellsHPV clearanceArm BNo significant differenceClinical surveillanceRate of HPV clearanceSecondary outcomesPre-neoplastic cervical lesionsCervical intraepithelial neoplasiaT cell infiltrationT cell responsesSignificant differenceCIN3 patientsIntraepithelial neoplasiaArm ACervical lesionsImiquimod groupSurveillance armVaginal suppositoriesProspective trialsArm CHPV vaccinationImiquimod
2012
Anterior pelvic exenteration with total vaginectomy for recurrent or persistent genitourinary malignancies: Review of surgical technique, complications, and outcome
Andikyan V, Khoury-Collado F, Gerst S, Talukdar S, Bochner B, Sandhu J, Abu-Rustum N, Sonoda Y, Barakat R, Chi D. Anterior pelvic exenteration with total vaginectomy for recurrent or persistent genitourinary malignancies: Review of surgical technique, complications, and outcome. Gynecologic Oncology 2012, 126: 346-350. PMID: 22555107, DOI: 10.1016/j.ygyno.2012.04.034.Peer-Reviewed Original ResearchConceptsAnterior pelvic exenterationPelvic exenterationTotal vaginectomyPelvic recurrencePostoperative complicationsGenitourinary malignanciesSurgical techniqueNegative pathologic marginsPreliminary survival dataMajor postoperative complicationsMedian tumor sizeEvidence of diseaseRate of readmissionComplete surgical resectionTotal pelvic exenterationCentral pelvic recurrencePrimary tumor sitePancreatic recurrenceOperative mortalityOncologic outcomesSurgical resectionMedian ageCase seriesPathologic marginsTumor sizeExtended pelvic resections for recurrent or persistent uterine and cervical malignancies: An update on out of the box surgery
Andikyan V, Khoury-Collado F, Sonoda Y, Gerst S, Alektiar K, Sandhu J, Bochner B, Barakat R, Boland P, Chi D. Extended pelvic resections for recurrent or persistent uterine and cervical malignancies: An update on out of the box surgery. Gynecologic Oncology 2012, 125: 404-408. PMID: 22285844, DOI: 10.1016/j.ygyno.2012.01.031.Peer-Reviewed Original ResearchConceptsExtended pelvic resectionR0 resectionPostoperative complicationsOverall survivalCervical malignancyPelvic resectionPositive pathologic marginsUterus/cervixMajor postoperative complicationsOutcomes of patientsComplete gross resectionKaplan-Meier methodMedian tumor diameterDays post surgeryEn bloc resectionMajor vascular structuresPrimary tumor siteUterus/Perioperative mortalityCommon morbidityGross resectionMedian agePeripheral neuropathyPost surgeryPelvic abscess
2003
Fluoreszenzdiagnostik mit 5-ALA-Thermogel bei zervikaler intraepithelialer Neoplasie
Andikyan V, Kronschnabl M, Hillemanns M, Wang X, Stepp H, Hillemanns P. Fluoreszenzdiagnostik mit 5-ALA-Thermogel bei zervikaler intraepithelialer Neoplasie. Gynäkologische Rundschau 2003, 44: 31-37. PMID: 14673226, DOI: 10.1159/000074315.Peer-Reviewed Original ResearchConceptsCervical intraepithelial neoplasiaNormal adjacent epitheliumCIN 3Female patientsIntraepithelial neoplasiaCIN 1CIN lesionsCervix uteriDysplastic epitheliumHistological examinationAdjacent epitheliumPorphyrin fluorescence intensityNormal ratioTumor selectivityDrug applicationBody temperatureLesionsPhotodynamic therapyGel formulationTwofold increaseEpitheliumEpithelial tissuesMaximal intensityFormulation 4